AbbVie Exercises Exclusive Option to License Argenx’s ARGX-115
AbbVie Exercises Exclusive Option to License Argenx’s ARGX-115
Shots:
- AbbVie will obtain a worldwide, exclusive license to develop and commercialize ARGX-115-based products
- Argenx to receive development, regulatory and commercial milestone payments of up to $625M, and has rights to co-promote ARGX-115 products in the EU and Swiss Economic Area
- Argenx and AbbVie previously entered into an option and license agreement for ARGX-115 in April 2016, for development and commercialization of ARGX-115
Click here to read full press release/ article | Ref: Argenx | Image: Cantilis
